Cytomegalovirus in pregnancy: to screen or not to screen

Susan Walker, Ricardo Palma-Dias, Erica Michelle Wood, Paul A Shekleton, Michelle Leanne Giles

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) infection is now the commonest congenital form of infective neurological handicap, recognized by the Institute of Medicine as the leading priority for the developed world in congenital infection. In the absence of an effective vaccine, universal screening for CMV in pregnancy has been proposed, in order that primary infection could be diagnosed and- potentially- the burden of disability due to congenital CMV prevented. Discussion: Universal screening for CMV to identify seronegative women at the beginning of pregnancy could potentially reduce the burden of congenital CMV in one of three ways. The risk of acquiring the infection during pregnancy has been shown to be reduced by institution of simple hygiene measures (primary prevention). Among women who seroconvert during pregnancy, CMV hyperimmune globulin (CMV HIG) shows promise in reducing the risk of perinatal transmission (secondary prevention), and CMV HIG and/ or antivirals may be effective in reducing the risk of clinical sequelae among those known to be infected (tertiary prevention). The reports from these studies have re-ignited interest in universal screening for CMV, but against the potential benefit of these exciting therapies needs to be weighed the challenges associated with the implementation of any universal screening in pregnancy. These include; the optimal test, and timing of screening, to maximize detection; an approach to the management of equivocal results, and the cost effectiveness of the proposed screening program. In this article, we provide an overview of current knowledge and ongoing trials in the prevention, diagnosis and management of congenital CMV. Recognising that CMV screening is already being offered to many patients on an ad hoc basis, we also provide a management algorithm to guide clinicians and assist in counseling patients. Summary: We suggest that- on the basis of current data- the criteria necessary to recommend universal screening for CMV ar
Original languageEnglish
Pages (from-to)1 - 8
Number of pages8
JournalBMC Pregnancy and Childbirth
Volume13
Issue numberArt. ID: 96
DOIs
Publication statusPublished - 2013

Cite this

Walker, Susan ; Palma-Dias, Ricardo ; Wood, Erica Michelle ; Shekleton, Paul A ; Giles, Michelle Leanne. / Cytomegalovirus in pregnancy: to screen or not to screen. In: BMC Pregnancy and Childbirth. 2013 ; Vol. 13, No. Art. ID: 96. pp. 1 - 8.
@article{61bdd97b52224df591a7f4898b5b3a73,
title = "Cytomegalovirus in pregnancy: to screen or not to screen",
abstract = "Cytomegalovirus (CMV) infection is now the commonest congenital form of infective neurological handicap, recognized by the Institute of Medicine as the leading priority for the developed world in congenital infection. In the absence of an effective vaccine, universal screening for CMV in pregnancy has been proposed, in order that primary infection could be diagnosed and- potentially- the burden of disability due to congenital CMV prevented. Discussion: Universal screening for CMV to identify seronegative women at the beginning of pregnancy could potentially reduce the burden of congenital CMV in one of three ways. The risk of acquiring the infection during pregnancy has been shown to be reduced by institution of simple hygiene measures (primary prevention). Among women who seroconvert during pregnancy, CMV hyperimmune globulin (CMV HIG) shows promise in reducing the risk of perinatal transmission (secondary prevention), and CMV HIG and/ or antivirals may be effective in reducing the risk of clinical sequelae among those known to be infected (tertiary prevention). The reports from these studies have re-ignited interest in universal screening for CMV, but against the potential benefit of these exciting therapies needs to be weighed the challenges associated with the implementation of any universal screening in pregnancy. These include; the optimal test, and timing of screening, to maximize detection; an approach to the management of equivocal results, and the cost effectiveness of the proposed screening program. In this article, we provide an overview of current knowledge and ongoing trials in the prevention, diagnosis and management of congenital CMV. Recognising that CMV screening is already being offered to many patients on an ad hoc basis, we also provide a management algorithm to guide clinicians and assist in counseling patients. Summary: We suggest that- on the basis of current data- the criteria necessary to recommend universal screening for CMV ar",
author = "Susan Walker and Ricardo Palma-Dias and Wood, {Erica Michelle} and Shekleton, {Paul A} and Giles, {Michelle Leanne}",
year = "2013",
doi = "10.1186/1471-2393-13-96",
language = "English",
volume = "13",
pages = "1 -- 8",
journal = "BMC Pregnancy and Childbirth",
issn = "1471-2393",
publisher = "Springer-Verlag London Ltd.",
number = "Art. ID: 96",

}

Cytomegalovirus in pregnancy: to screen or not to screen. / Walker, Susan; Palma-Dias, Ricardo; Wood, Erica Michelle; Shekleton, Paul A; Giles, Michelle Leanne.

In: BMC Pregnancy and Childbirth, Vol. 13, No. Art. ID: 96, 2013, p. 1 - 8.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cytomegalovirus in pregnancy: to screen or not to screen

AU - Walker, Susan

AU - Palma-Dias, Ricardo

AU - Wood, Erica Michelle

AU - Shekleton, Paul A

AU - Giles, Michelle Leanne

PY - 2013

Y1 - 2013

N2 - Cytomegalovirus (CMV) infection is now the commonest congenital form of infective neurological handicap, recognized by the Institute of Medicine as the leading priority for the developed world in congenital infection. In the absence of an effective vaccine, universal screening for CMV in pregnancy has been proposed, in order that primary infection could be diagnosed and- potentially- the burden of disability due to congenital CMV prevented. Discussion: Universal screening for CMV to identify seronegative women at the beginning of pregnancy could potentially reduce the burden of congenital CMV in one of three ways. The risk of acquiring the infection during pregnancy has been shown to be reduced by institution of simple hygiene measures (primary prevention). Among women who seroconvert during pregnancy, CMV hyperimmune globulin (CMV HIG) shows promise in reducing the risk of perinatal transmission (secondary prevention), and CMV HIG and/ or antivirals may be effective in reducing the risk of clinical sequelae among those known to be infected (tertiary prevention). The reports from these studies have re-ignited interest in universal screening for CMV, but against the potential benefit of these exciting therapies needs to be weighed the challenges associated with the implementation of any universal screening in pregnancy. These include; the optimal test, and timing of screening, to maximize detection; an approach to the management of equivocal results, and the cost effectiveness of the proposed screening program. In this article, we provide an overview of current knowledge and ongoing trials in the prevention, diagnosis and management of congenital CMV. Recognising that CMV screening is already being offered to many patients on an ad hoc basis, we also provide a management algorithm to guide clinicians and assist in counseling patients. Summary: We suggest that- on the basis of current data- the criteria necessary to recommend universal screening for CMV ar

AB - Cytomegalovirus (CMV) infection is now the commonest congenital form of infective neurological handicap, recognized by the Institute of Medicine as the leading priority for the developed world in congenital infection. In the absence of an effective vaccine, universal screening for CMV in pregnancy has been proposed, in order that primary infection could be diagnosed and- potentially- the burden of disability due to congenital CMV prevented. Discussion: Universal screening for CMV to identify seronegative women at the beginning of pregnancy could potentially reduce the burden of congenital CMV in one of three ways. The risk of acquiring the infection during pregnancy has been shown to be reduced by institution of simple hygiene measures (primary prevention). Among women who seroconvert during pregnancy, CMV hyperimmune globulin (CMV HIG) shows promise in reducing the risk of perinatal transmission (secondary prevention), and CMV HIG and/ or antivirals may be effective in reducing the risk of clinical sequelae among those known to be infected (tertiary prevention). The reports from these studies have re-ignited interest in universal screening for CMV, but against the potential benefit of these exciting therapies needs to be weighed the challenges associated with the implementation of any universal screening in pregnancy. These include; the optimal test, and timing of screening, to maximize detection; an approach to the management of equivocal results, and the cost effectiveness of the proposed screening program. In this article, we provide an overview of current knowledge and ongoing trials in the prevention, diagnosis and management of congenital CMV. Recognising that CMV screening is already being offered to many patients on an ad hoc basis, we also provide a management algorithm to guide clinicians and assist in counseling patients. Summary: We suggest that- on the basis of current data- the criteria necessary to recommend universal screening for CMV ar

UR - http://www.biomedcentral.com/content/pdf/1471-2393-13-96.pdf

U2 - 10.1186/1471-2393-13-96

DO - 10.1186/1471-2393-13-96

M3 - Article

VL - 13

SP - 1

EP - 8

JO - BMC Pregnancy and Childbirth

JF - BMC Pregnancy and Childbirth

SN - 1471-2393

IS - Art. ID: 96

ER -